NCT07054047Not yet recruiting
Improving Diagnosis and Treatment for Patients With Rectal Cancer
Improving the Prognostic Accuracy of Staging Rectal Cancer Using Magnetic Resonance Imaging (MRI) - Detected Tumour Deposits and Vascular Invasion (mrTDV) Instead of Tumour Nodal Metastasis (mrTNM)
Source: ClinicalTrials.gov · Last updated 8 Jul 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The cancer stage information from scans guides pre-operative treatment and the type of surgery offered. The investigators are studying whether a new Magnetic Resonance Imaging (MRI) staging method can improve the accuracy of prognosis for patients diagnosed with rectal cancer. The investigators will provide consultant radiologists with the know-how to report MRI scans using this new method and compare this with the existing method. This study will test this by comparing how accurately the old versus new method predict the outcomes of patients. The existing method relies on radiologists determining if tumour has spread through the bowel wall or not and whether there are suspected malignant lymph nodes. The new method looks for tumour spread into the veins and whether or not there are tumour deposits. Our previous research has shown that the new method is much more accurate at predicting prognosis, but this finding needs to be verified by a larger multicentre study. The investigators are also studying the patient journey, so the investigators can better understand patients' experiences and the impact that treatments have on their quality of life. The investigators wish to understand if improvements in the accuracy of prognosis from scans could change treatment decisions in future. The investigators will also compare the radiology scan prediction of prognostic factors by looking carefully at the tumour specimens.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 438 (estimated)
- First submitted
- 17 Jun 2025
- Start date
- 1 Jul 2025
- Primary completion date
- 31 May 2026
- Lead sponsor
- Imperial College London
- Diseases
- Colorectal cancer, Childhood cancers
- NCT number
- NCT07054047
What you commit to
- Study type: Interventional
- Planned participants: 438
- From 1 Jul 2025 to the primary completion date, 31 May 2026
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Have irresectable metastatic disease at time of initial staging
- Undergoing palliative treatment for Rectal Cancer
- Have a biopsy-proven rectal malignancy which is not adenocarcinoma
Other
- Are contraindicated for MRI staging
Who the study is looking for
- Have a rectal cancer proven on biopsy or subsequent surgery
- Sites able to submit anonymised MRI staging scans, pathology and imaging reports for central review
- Aged 16 years or over
Age in the registry: 16 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| John Radcliffe Hospital Coordinator of this site? Confirm its status | Oxford | United Kingdom | Unknown status |
| Salisbury District Hospital Coordinator of this site? Confirm its status | Salisbury | United Kingdom | Unknown status |
| Southampton General Hospital Coordinator of this site? Confirm its status | Southampton | United Kingdom | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.